Search
Search Results
-
Soft Tissue Sarcoma
Soft tissue sarcomas are rare mesenchymal malignancies made up of several heterogeneous subtypes with distinct clinicopathologic features....
-
Differentiation of benign and metastatic lymph nodes in soft tissue sarcoma
Lymph node metastasis (LNM) occurs in less than 5% of soft tissue sarcoma (STS) patients and indicates an aggressive course of disease. Suspicious...
-
PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma
BackgroundWe aimed to examine whether PTEN pathogenic variants (mutPTEN) were associated with overall survival (OS) in patients with advanced soft...
-
Tumor Immune Microenvironment of Soft Tissue Sarcoma
Soft tissue sarcoma (STS) is a group of cancers transformed from mesenchymal cells. The treatment outcome of immunotherapy has not been as successful...
-
The Effect of chemo- and radiotherapy on tumor necrosis in soft tissue sarcoma– does it influence prognosis?
BackgroundSoft tissue sarcomas (STSs) are a heterogeneous group of tumors. Wide surgical resection is standard, often combined with neoadjuvant...
-
Photon and Proton irradiation in Patient-derived, Three-Dimensional Soft Tissue Sarcoma Models
BackgroundDespite their heterogeneity, the current standard preoperative radiotherapy regimen for localized high-grade soft tissue sarcoma (STS)...
-
Prospective phase II trial of preoperative hypofractionated proton therapy for extremity and truncal soft tissue sarcoma: the PRONTO study rationale and design
BackgroundOncologic surgical resection is the standard of care for extremity and truncal soft tissue sarcoma (STS), often accompanied by the addition...
-
UK guidelines for the management of soft tissue sarcomas
Soft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues and can occur almost anywhere in the body. Their rarity, and the...
-
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
BackgroundAxitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic...
-
Amputation in patients with extremity soft tissue sarcoma: the experience of an East Asian referral center
BackgroundThis study aimed to investigate the characteristics and clinical outcomes in a series of patients with extremity soft tissue sarcoma (STS)...
-
Postoperative complications and oncologic outcomes after multimodal therapy of localized high risk soft tissue sarcoma
BackgroundStandard therapy for localized high-risk soft tissue sarcoma includes surgical resection and neoadjuvant or adjuvant radiation therapy...
-
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)
BackgroundMetastatic soft tissue sarcoma (STS) are a heterogeneous group of malignancies which are not curable with chemotherapy alone. Therefore,...
-
Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?
BackgroundCoagulation and fibrinolysis are distinct processes that are highly correlated. Cells control coagulation and fibrinolysis by expression of...
-
Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial
BackgroundThe standard of care treatment for soft tissue sarcoma of the extremities is a wide resection in combination with pre- or postoperative...
-
The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma
BackgroundStandard treatment of soft tissue sarcoma (STS) of the extremities includes limb-sparing surgery combined with pre- or postoperative...
-
Performance of Sonoelastography for predicting malignancy in soft tissue
BackgroundSeparating benign from malignant soft-tissue masses often requires a biopsy. The objective of this study was to assess whether shear-wave...
-
Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma
BackgroundSoft tissue sarcomas (STS) are rare, heterogeneous tumours and biomarkers are needed to inform management. We previously derived a...
-
Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study
BackgroundAlveolar soft part sarcoma (ASPS) is a rare histological subtype of soft-tissue sarcoma, which remains refractory to conventional cytotoxic...
-
Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib
BackgroundSoft tissue sarcomas (STS) are a rare type of malignancy comprising a variety of histological diagnoses. Chemotherapy constitutes the...
-
Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma
BackgroundSoft tissue sarcomas (STS), have significant inter- and intra-tumoral heterogeneity, with poor response to standard neoadjuvant...
